Decrease in quality of life predicts mortality in adult patients with pulmonary arterial hypertension due to congenital heart disease

I.M. Blok · A.C.M.J. van Riel · M.J. Schuuring · M.G. Duffels · J.C. Vis · A.P.J. van Dijk · E.S. Hoendermis · B.J.M. Mulder · B.J. Bouma

Published online: 4 March 2015
© The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract

Background Decrease in quality of life (QoL) in left-sided heart failure precedes poor survival, which can be reversed with exercise training. We investigated whether QoL is associated with mortality in pulmonary arterial hypertension due to congenital heart disease (PAH-CHD) patients.

Methods In this observational study, PAH-CHD adults referred for PAH-specific therapy were included. QoL surveys (SF36) were recorded during 2 years of therapy. Based on shift in SF36 scores during this period, patients had either decreased or non-decreased QoL. Subsequently, the patients were followed for mortality.

Results Thirty-nine PAH-CHD patients (mean age 42, 44% male, 49% Down’s syndrome) were analysed. Following PAH-specific therapy, SF36 physical component summary (PCS) decreased in 13 (35–31 points, \( p = 0.001 \)) and showed no decrease in 26 patients (34–43 points, mean values, \( p < 0.001 \)). Post-initiation phase, median follow-up was 4.5 years, during which 12 deaths occurred (31%), 10 (56%) in the decreased and 2 (10%) in the non-decreased group (\( p = 0.002 \)). Cox regression showed a decrease in SF36 PCS predicted mortality (HR 3.4, 95% CI 1.03–11, \( p = 0.045 \)).

Conclusions In PAH-CHD patients, decrease in SF36 PCS following initiation of PAH-specific therapy is a determinant of mortality.

Keywords Congenital heart defect · Pulmonary arterial hypertension · Quality of life · Serial · Mortality

What is already known about this subject?

Patients with pulmonary arterial hypertension due to congenital heart disease (PAH-CHD) exhibit high morbidity and mortality. PAH-specific therapy has become the cornerstone in the management of these patients due to beneficial effects on symptoms, haemodynamics and quality of life (QoL). In patients with left-sided heart failure a decrease in QoL is associated with higher mortality, but exercise training in these patients improves both QoL and mortality. It is currently unclear whether these findings are applicable to the PAH-CHD population, and whether QoL monitoring in these patients can identify those with a poor prognosis. Therefore, we investigated whether a decrease in QoL in adult PAH-CHD patients is associated with late mortality.
What does this study add?

Our study is the first to report that decrease in QoL is a predictor for late mortality in PAH-CHD.

How might this impact on clinical practice?

We recommend periodical assessment of QoL in PAH-CHD patients to facilitate early recognition of disease progression.

Introduction

Adults with congenital heart disease (CHD) have a lower life expectancy than their healthy counterparts [1], especially when pulmonary arterial hypertension (PAH) develops [2–7]. PAH-specific therapy has become the cornerstone in the management of these patients because of its beneficial effects on disease symptoms, haemodynamics and quality of life (QoL) [3, 8–10]. However, life expectancy and QoL still remain markedly impaired.

In patients with acquired heart failure, several studies found an association between baseline QoL and mortality [11, 12]. In addition, a decrease in QoL over time was significantly associated with increased mortality in these patients [13], suggesting QoL may identify patients in need for interventions to improve their survival. Furthermore, several studies in acquired heart failure revealed that survival and QoL can be improved by exercise training [14–16]. Thus, QoL has the potential to serve as both an important determinant for mortality and a therapeutic target for treatment. The current study aims to investigate whether a decrease in QoL in adult PAH-CHD patients is associated with late mortality.

Methods

Study population

This was a prospective multicentre observational study of adult patients with PAH associated with CHD, including patients with Down’s syndrome [17, 18], referred for PAH-specific therapy between January 2005 and May 2013. The current QoL study was part of an ongoing non-randomised trial on PAH-specific therapy in PAH-CHD patients [5]. Patients with all kinds of structural heart defects, including closed defects, could be enrolled. PAH was defined upon the echocardiographic PAH probability (tricuspid regurgitation velocity ≥ 2.9 m/s).

Study protocol

In the initiation phase of the study, PAH-specific therapy was started according to a standardised protocol [5]. This included the conduction of QoL questionnaires at standardised time intervals. After the initiation phase those QoL questionnaires were used to form individual QoL regression lines in order to divide patients into either a decreased or non-decreased QoL group. Relevant improvement or decrease of QoL was defined as more than two points change during the initiation phase. Baseline (T0) was defined as the start of follow-up to determine survival, which was 2 years after the initiation phase in each patient.

According to the treatment protocol, patients were evaluated with clinical examination, determination of functional class, 6-min walk distance (6-MWD), echocardiography, laboratory tests (including N-terminal pro-brain natriuretic peptide (NT-pro-BNP)) and quality of life questionnaires. These tests were all conducted 24, 21, 18, 15 and 12 months before T0 and at T0, apart from echocardiography which was performed twice a year.

Quality of life was evaluated using the 36-Item Short Form Health Survey (SF36), a well-documented, widely used and validated, self-administered QoL scoring system. It incorporated both a physical and mental component summary (PCS and MCS), thus reflecting physical and mental health. The QoL questionnaires were filled out by the patient or, in case of Down’s syndrome, the patient’s parent or guardian. Survival and in case of death, time and causes of death during follow-up were obtained from the participating hospitals until March 2014. Doppler echocardiography (VIVID 7 General Electric, USA) was performed to evaluate right ventricular function, using tricuspid annular plane systolic excursion (TAPSE) from M-mode recordings. Systolic pulmonary artery pressure was obtained from Doppler recording using the modified Bernoulli equation.

Statistical analysis

Descriptive data were presented as mean±SD if normally distributed or median with IQR, as appropriate. Categorical data were evaluated using the chi-square statistic. The change of continuous variables was evaluated using a two-tailed paired t test. Independent sample t test or Mann-Whitney U test was used for comparison of continuous variables between two groups. Spearman’s analysis was used for correlation of numerous variables, as appropriate. Time to event analysis was performed with Kaplan-Meier estimates of survival. Log-rank test was performed to determine significant differences in mortality rate between the two groups. The associations between predictors and mortality were evaluated using univariate Cox regression analysis. All reported p values are two-sided, and values of p<0.05 are considered significant.
were considered significant. Statistical analysis was performed with SPSS 20.0 (IBM Corp, Armonk, NY). Since this study focused on shift in QoL, only data from patients who returned more than one questionnaire were used in the final analysis.

Results

Patient cohort

Ninety-one adults (42 ± 14 year) with PAH-CHD were included (Fig. 1), divided over Amsterdam (64), Nijmegen (15) and Groningen (12). One patient refused treatment initiation. In five patients health insurance refused reimbursement of treatment. In total 85 patients started standardised PAH-specific therapy (initiation phase). Of these, 61 (72 %) patients returned the first QoL questionnaire. Baseline characteristics of these 61 patients are described in the supplementary data (Table S1). In the 61 patients returning the first QoL questionnaire, no differences in QoL were found among those who continued and those who were lost to follow-up, for either the SF36 PCS (mean values 35–35 respectively, \( p = 0.930 \)) or SF36 MCS (mean values 50–48 respectively, \( p = 0.426 \)). In total 39 PAH-CHD patients (mean age 42 ± 12, 44 % male, 49 % Down’s syndrome) completed the initiation phase and their data were used for the final analysis.

Baseline characteristics at T0 are summarised in Table 1. Based on their individual SF36 PCS regression lines during the two-year initiation phase (Fig. 2a), patients were divided into two groups. Group 1 consisted of patients with decreased (Fig. 2b) and group 2 of patients without decreased SF36 PCS regression lines (Fig. 2c). At T0 mean SF36 PCS was 38 ± 12 (range 10.96–58.32, \( n = 39 \)), which is more than one SD lower than the general population. SF36 MCS was 49 ± 13 (22.96–66.79, \( n = 39 \)), which closely resembles the mean score of the general population. The two groups, based on either decreased or non-decreased SF36 PCS, were well balanced with respect to most clinical characteristics. However, patients with decreased SF36 PCS had a lower baseline 6-MWD (\( p = 0.009 \)) and New York Heart Association (NYHA) class (\( p = 0.006 \)), compared with patients without a decrease. In contrast, no relation was found between change in SF36 PCS and change in 6-MWD (\( r = 0.12, p = 0.468 \)).

The 39 patients who finished the initiation phase completed 131 questionnaires (median 4, range 2–5). In 13 patients the SF36 PCS decreased by a mean of ten points (mean values 36–26, \( p = 0.006 \)). In the 26 patients without a decrease, QoL improved in 20 patients (mean values 36–47, \( p = 0.006 \)) and remained stable in 6 (mean values 31–33, \( p = 0.344 \)). Decrease in SF36 PCS was equally distributed in patients with (53 %) and without (40 %) Down’s syndrome (\( p = 0.429 \)). The effect size of decrease was similar in both groups (mean differences 5.3 and 5.1, respectively). Figure 3 shows the variability of the QoL scores during the initiation phase.

Mortality

During a median follow-up of 4.5 (range 0.3–6.4) years, total all-cause mortality was 31 % (12 deaths). Median time until death was 2.3 years. No patients died during the two-year initiation phase. Two (10 %) patients died in the non-decreased and ten (56 %) in the decreased QoL group (\( p = 0.002 \)). Causes of death were right-sided heart failure (\( n = 7 \)), sudden cardiac death (\( n = 2 \)), sepsis (\( n = 1 \)) and unknown (\( n = 2 \)). Five-year mortality for all patients was 18 %. Seven out of 19 patients with Down’s syndrome died during follow-up compared with 5 out of 20 non-Down patients (\( p = 0.423 \)).

Using univariate Cox regression analysis, the significant determinants of mortality were age, NYHA classification, NT-pro-BNP, 6-MWD and decrease in SF36 PCS (Table 2). Patients with a decrease in SF36 PCS had a 5-year survival of 29 % compared with 74 % in those without a decrease in SF36 PCS (Fig. 4).
Our finding is in line with previous studies demonstrating an association between QoL and mortality, in healthy people [19] and in patients with acquired heart disease [11, 12, 20]. The above-mentioned studies used single instead of serial QoL measurements. In 2013, Apers et al. proposed that serial follow-up on QoL could be of more value than single measurements [21]. Four studies examined QoL with serial follow-up in CHD. They identified psychosocial determinants of baseline and serial QoL [22, 23], analysed associations between QoL and exercise capacity over time [24].

**Table 1** Baseline characteristics at T0

| Variables                      | All patients | Group 1 (decreased QoL) | Group 2 (non-decreased QoL) | p  |
|-------------------------------|--------------|-------------------------|-----------------------------|----|
| Number                        | 39           | 13                      | 26                          |    |
| Age, mean± SD (years)         | 42±12        | 43±10                   | 42±13                       | 0.929 |
| Male, n (%)                   | 17 (44)      | 7 (54)                  | 10 (39)                     | 0.361 |
| Down’s syndrome, n (%)        | 19 (49)      | 8 (62)                  | 11 (42)                     | 0.257 |
| Eisenmenger’s syndrome, n (%) | 35 (90)      | 13 (100)                | 22 (85)                     | 0.135 |
| Body mass index, mean± SD (kg)| 24±4         | 25±3                    | 24±4                        | 0.731 |
| NYHA class III or IV, n (%)   | 15 (43)      | 9 (75)                  | 6 (26)                      | 0.006 |
| SF36 PCS, mean± SD            | 38±12        | 31±11                   | 41±11                       | 0.010 |
| SF36 MCS, mean± SD            | 49±13        | 48±13                   | 50±13                       | 0.716 |

Medication

- **Bosentan, n (%)**
  - 36 (92)
  - 13 (100)
  - 23 (89)
  - 0.202
- **Diuretics, n (%)**
  - 15 (39)
  - 5 (39)
  - 10 (39)
  - 1.000
- **Cardiac surgery, n (%)**
  - 8 (23)
  - 2 (17)
  - 6 (26)
  - 0.529
- **Age surgery, median (range) (years)**
  - 6 (1–66)
  - 5 (2–7)
  - 8 (1–66)
  - 0.643
- **Saturation in rest, mean± SD (%)**
  - 85±6
  - 86±6
  - 85±7
  - 0.651
- **NT-pro-BNP, median (IQR) (ng/l)**
  - 429 (189–1197)
  - 508 (270–1011)
  - 382 (172–1263)
  - 0.353
- **6-MWD, mean± SD, (m)**
  - 385±129
  - 311±112
  - 422±123
  - 0.009
- **TAPSE, mean± SD, mm**
  - 19±6
  - 19±7
  - 19±5
  - 0.785
- **SPAP, mean± SD (mmHg)**
  - 93±17
  - 98±17
  - 90±17
  - 0.212

Shunt type

- **Pre tricuspid, n (%)**
  - 6 (15)
  - 2 (15)
  - 4 (15)
  - 0.760
- **Post tricuspid, n (%)**
  - 18 (46)
  - 5 (39)
  - 13 (50)
  - 0.760
- **Complexa, n (%)**
  - 15 (39)
  - 6 (46)
  - 9 (35)

**SF36 PCS** short form health survey of physical health; **SF36 MCS** short form health survey of mental health; **SD** standard deviation; **IQR** interquartile range; **QoL** quality of life; **6-MWD** six-minute walk distance; **SPAP** systolic pulmonary artery pressure; **TAPSE** tricuspid annular plane systolic excursion; **NT-pro-BNP** N-terminal pro-brain natriuretic peptide; **NYHA functional class** New York Heart Association functional class

*aComplex shunts included atrioventricular septal defect and univentricular heart

**Fig. 2**

- **a** Individual SF36 PCS regression lines of 39 PAH-CHD patients.
- **b** Decreased SF36 PCS regression lines, 13 patients.
- **c** Non-decreased SF36 PCS regression lines, 26 patients. All QoL measurements were recorded in the initiation phase after the start of PAH-specific standardised therapy. The thick lines represent the mean regression lines.

**Discussion**

**Quality of life and mortality**

The current study shows, for the first time, that a decrease in QoL on the physical component of the SF36 during the initiation phase of PAH-specific therapy in adult PAH-CHD patients is associated with late mortality. Patients with a decrease in SF36 PCS had a 5-year survival of 29% compared with 74% in those without a decrease in SF36 PCS. Our finding is in line with previous studies demonstrating an association between QoL and mortality, in healthy people [19] and in patients with acquired heart disease [11, 12, 20]. The above-mentioned studies used single instead of serial QoL measurements. In 2013, Apers et al. proposed that serial follow-up on QoL could be of more value than single measurements [21]. Four studies examined QoL with serial follow-up in CHD. They identified psychosocial determinants of baseline and serial QoL [22, 23], analysed associations between QoL and exercise capacity over time [24].
advanced disease. However, if decrease in QoL were merely a proxy for disease severity, one would expect baseline SF36 PCS to predict mortality as well and this was not the case. Given the results described above, we suggest the use of serial QoL follow-up in clinical practice to determine a patient’s mortality. The relationship between decrease in QoL and late mortality in adult PAH-CHD patients, as shown in our study, emphasises the importance of screening for decrease in QoL since periodical assessment could facilitate an early recognition of disease progression. A critical question is whether survival can be optimised in patients with disease progression. The use of knowledge from other areas of heart disease can be important for this task. In patients with

and provided insight into the longitudinal course of QoL [25]. None of these studies evaluated mortality. We, however, demonstrate that assessing QoL with serial follow-up provides useful information about late mortality, suggesting that serial follow-up may be a robust guide to clinical management in CHD patients. The use of patient-reported outcomes such as QoL instruments in clinical practice could help to screen for functional problems, to monitor disease progression or treatment effect, to stratify patients according to mortality risk and to guide clinical management.

In order to implement serial QoL follow-up in clinical practice, its predictive value for mortality has to be weighed against traditional determinants of mortality in PAH-CHD. Unfortunately, multivariate regression analysis could not be performed in our study due to the small number of events. However, despite our number of events, decrease in QoL was significantly associated with mortality, making it a promising determinant.

It is possible that physical quality of life is a proxy for disease severity. In accordance, patients with decreased QoL on the physical component of the SF36 in our study had a lower 6-MWD and worse NYHA class implying more

| Determinants of survival at T0 in 39 PAH-CHD patients | Univariate analysis |
|-------------------------------------------------------|---------------------|
| HR | 95 % CI | p |
|---|---|---|
| Male gender | 1.11 | 0.36–3.44 | 0.863 |
| Age, per 5 years | 1.29 | 1.06–1.56 | 0.009 |
| Saturation at rest | 1.02 | 0.94–1.12 | 0.594 |
| Ferritin (µg/L) | 0.99 | 0.97–1.02 | 0.613 |
| NYHA 3 or 4 | 4.50 | 1.30–15.56 | 0.018 |
| NT-pro-BNP, per 500 ng/L | 1.15 | 1.04–1.27 | 0.005 |
| 6-MWD, per 10 m | 0.92 | 0.87–0.97 | 0.003 |
| SPAP (mmHg) | 1.01 | 0.97–1.04 | 0.673 |
| TAPSE (mm) | 0.89 | 0.78–1.02 | 0.097 |
| QoL PCS | 0.98 | 0.91–1.05 | 0.534 |
| QoL MCS | 1.01 | 0.95–1.07 | 0.768 |
| Decreasing saturation at rest | 0.93 | 0.28–3.05 | 0.898 |
| Decreasing NT-pro-BNP | 0.91 | 0.27–3.04 | 0.874 |
| Decreasing NYHA class | 0.45 | 0.10–2.06 | 0.304 |
| Decreasing 6-MWD | 2.78 | 0.85–9.16 | 0.092 |
| Decreasing SPAP | 0.68 | 0.22–2.15 | 0.511 |
| Decreasing TAPSE | 2.82 | 0.75–10.64 | 0.126 |
| Decreasing QoL PCS | 3.38 | 1.03–11.12 | 0.045 |
| Decreasing QoL MCS | 1.61 | 0.43–5.95 | 0.478 |

HR hazard ratio; QoL quality of life; PCS physical summary score; MCS mental summary score; 6-MWD 6-min walk distance; SPAP systolic pulmonary artery pressure; TAPSE tricuspid annular plane systolic excursion; NYHA functional class New York Heart Association functional class; NT-pro-BNP N-terminal pro-brain natriuretic peptide
acquired heart failure, baseline QoL was found to be a reliable determinant for mortality [11, 12]. Additionally, a study by Lupon et al. in 1151 heart failure patients focused on shift in QoL [13]. They used Minnesota QoL questionnaires for up to 5 years with extended follow-up to 6 years for prognosis assessment. During this period 457 deaths were recorded. A decrease in QoL (score deterioration of ≥10%) was associated with impaired 12-month survival (HR 1.012, 95% CI 1.006–1.018, p < 0.001). On top of QoL serving as a determinant for mortality, three other studies reported that stimulation of physical activity has shown to be effective for improving QoL, as well as mortality [14–16]. It might be interesting for future studies in PAH-CHD patients to evaluate whether an improvement of QoL influences survival.

Study limitations

Quality of life questionnaires have not been properly validated in patients with Down’s syndrome. To address this problem and increase their validity, QoL questionnaires were filled in by the patient’s parent or guardian. Since self-reports are impossible in these patients, even though the SF36 has not been validated for proxy report, it is the most appropriate way to evaluate QoL in Down’s syndrome patients. This approach has yielded favourable results in earlier studies [3, 5, 26] and makes sure new scientific insights are also gained for patients with Down’s syndrome. In this study, decrease in SF36 PCS was equally distributed and had a similar effect size for both Down and non-Down patients. However, further research is crucial to determine the value of questionnaires by proxy reports.

Although our study comprises the largest Dutch cohort of PAH-CHD patients, we were unfortunately unable to perform multivariate regression analysis due to the number of events.

Finally, invasive haemodynamics are recommended in the guidelines for the diagnosis of PAH [27, 28]. However, echocardiography is an adequate non-invasive modality in patients with evident diagnosis of PAH [29, 30] in patients with CHD. Due to the higher complication risk in patients with PAH-CHD cardiac catheterisation was not routinely performed in these patients, but only if the diagnosis of PAH was not clearly evident at echocardiography.

Conclusion

A decrease in QoL on the physical component of the SF36 after the initiation of PAH-specific therapy in adult PAH-CHD patients predicts mortality. Patients with a decrease in SF36 PCS during the initiation phase have a 5-year survival of 29% compared with 74% in those without a decrease in SF36 PCS. Periodical assessment of quality of life in PAH-CHD patients could facilitate early recognition of disease progression. Based on the association between QoL and mortality, it might be interesting for future studies in PAH-CHD patients to evaluate whether interventions to improve QoL might influence survival.

Acknowledgements The work described in this study was carried out in the context of the Parelsnoer Institute (PSI). PSI is part of and funded by the Dutch Federation of University Medical Centres. This work was supported by an unrestricted grant from Actelion Pharmaceuticals.

Funding This work was supported by an unrestricted grant from Actelion Pharmaceuticals.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Oechslin EN, Harrison DA, Connelly MS, Webb GD, Siu SC. Mode of death in adults with congenital heart disease. Am J Cardiol. 2000;86:1111–6.
2. Radke RM, Diller G-P, Baumgartner H. The challenge of managing pulmonary arterial hypertension in adults with congenital heart disease. Expert Rev Cardiovasc Ther. 2013;11:919–31.
3. Duffels MGJ, Vis JC, van Loon RLE, et al. Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down’s syndrome. Am J Cardiol. 2009;103:1309–15.
4. Duffels MGJ, Engelfriet PM, Berger RMF, et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. Int J Cardiol. 2007;120:198–204.
5. Vis JC, Duffels MG, Mulder P, et al. Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease. Int J Cardiol. 2013;164:64–9.
6. Schuurng MJ, van Riel ACMJ, Vis JC, et al. High-sensitivity troponin T is associated with poor outcome in adults with pulmonary arterial hypertension due to congenital heart disease. Congenit Heart Dis. 2013;8:520–6.
7. Lange SA, Braun MU, Schoen SP, Strasser RH. Latent pulmonary hypertension in atrial septal defect: Dynamic stress echocardiography reveals unapparent pulmonary hypertension and confirms rapid normalisation after ASD closure. Neth Heart J. 2013;21:333–43.
8. Galié N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371:2093–100.
9. Galié N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114:48–54.
10. Schuurung MJ, Vis JC, Duffels MG, Bouma BJ, Mulder BJ. Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan. Ther Clin Risk Manag. 2010;6:359–66.
11. Friedmann E, Thomas SA, Liu F, et al. Relationship of depression, anxiety, and social isolation to chronic heart failure outpatient mortality. Am Heart J. 2006;152:940.e1–8.
12. Frasure-Smith N, Léspérance F, Habra M, et al. Elevated depression symptoms predict long-term cardiovascular mortality in patients with atrial fibrillation and heart failure. Circulation. 2009;120:134–40.

13. Lupón J, Gastelurrutia P, de Antonio M, et al. Quality of life monitoring in ambulatory heart failure patients: temporal changes and prognostic value. Eur J Heart Fail. 2013;15:103–9.

14. Carlsson S, Andersson T, Lichtenstein P, Michäelsson K, Ahlbom A. Physical activity and mortality: is the association explained by genetic selection? Am J Epidemiol. 2007;166:255–9.

15. Pepoli MF, Davos C, Francis DP, Coats AJ. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ. 2004;328:189–96.

16. Coats AJ, Adamopoulos S, Radaelli A, et al. Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation, and autonomic function. Circulation. 1992;85:2119–31.

17. Duffels MGJ, Vis JC, van Loon RLE, et al. Down patients with Eisenmenger syndrome: is bosentan treatment an option? Int J Cardiol. 2009;134:378–83.

18. Vis JC, de Bruin-Bon RH, Bouma BJ, et al. Congenital heart defects are under-recognised in adult patients with Down’s syndrome. Heart. 2010;96:1480–4.

19. Feeny D, Huguet N, McFarland BH, et al. Hearing, mobility, and pain predict mortality: a longitudinal population-based study. J Clin Epidemiol. 2012;65:764–77.

20. Schron E, Friedmann E, Thomas SA. Does health-related quality of life predict hospitalization or mortality in patients with atrial fibrillation? J Cardiovasc Electrophysiol. 2014;25:23–8.

21. Apers S, Luyckx K, Moons P. Quality of life in adult congenital heart disease: what do we already know and what do we still need to know? Curr Cardiol Rep. 2013;15:407–12.

22. Luyckx K, Missotten L, Goossens E, Moons P. Individual and contextual determinants of quality of life in adolescents with congenital heart disease. J Adolesc Health. 2012;51:122–8.

23. Neuner B, Busch MA, Singer S, et al. Sense of coherence as a predictor of quality of life in adolescents with congenital heart defects: a register-based 1-year follow-up study. J Dev Behav Pediatr. 2011;32:316–27.

24. Cícero C, Franchi SM, Barreto AC, Lopes AAB. Lack of tight association between quality of life and exercise capacity in pulmonary arterial hypertension. Arq Bras Cardiol. 2012;99:876–85.

25. Van Rijen EHM, Utens EMWJ, Roos-Hesselink JW, et al. Current subjective state of health, and longitudinal psychological well-being over a period of 10 years, in a cohort of adults with congenital cardiac disease. Cardiol Young. 2005;15:168–75.

26. Glenn S, Cunningham C, Nananidou A, Prasher V, Glenholmes P. Using the strengths and difficulties questionnaire with adults with Down’s syndrome. Res Dev Disabil. 2013;34:3343–51.

27. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493–537.

28. Post MC. Association between pulmonary hypertension and an atrial septal defect. Neth Heart J. 2013;21:331–2.

29. Eysmann SB, Palevsky HI, Reichek N, Hackney K, Douglas PS. Two-dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension. Circulation. 1989;80:353–60.

30. Van Riel ACMJ, Schuuring MJ, van Hessen ID, et al. Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification. Int J Cardiol. 2014;174:299–305.